细胞程序性死亡蛋白1配体1(PDL1)真核蛋白

Eukaryotic Programmed Cell Death Protein 1 Ligand 1 (PDL1)

CD274; PDCD1LG1; B7-H; B7H1; PD-L1; PDCD1L1; PDCD1-LG1; Programed Death Ligand 1

  • 细胞程序性死亡蛋白1配体1(PDL1)真核蛋白 产品包装(模拟)
  • 细胞程序性死亡蛋白1配体1(PDL1)真核蛋白 产品包装(模拟)
  • EPA788Hu61.jpg Figure. SDS-PAGE
  • Certificate 通过ISO 9001、ISO 13485质量体系认证

序列

用法

Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

储存

避免反复冻融。2-8°C不超过一个月，-80°C不超过12个月。

稳定性

热稳定性以损失率显示。损失率是由加速降解试验决定，具体方法如下：在37°C孵育48小时，没有显著的降解或者沉淀产生。保质期内，在适当的条件下存储，损失率低于5%。

相关产品

编号 适用物种：Homo sapiens (Human，人) 应用(仅供研究使用，不用于临床诊断！)
RPA788Hu02 细胞程序性死亡蛋白1配体1(PDL1)重组蛋白 Positive Control; Immunogen; SDS-PAGE; WB.
RPA788Hu01 细胞程序性死亡蛋白1配体1(PDL1)重组蛋白 Positive Control; Immunogen; SDS-PAGE; WB.
APA788Hu61 细胞程序性死亡蛋白1配体1(PDL1)活性蛋白 Cell culture; Activity Assays.
EPA788Hu61 细胞程序性死亡蛋白1配体1(PDL1)真核蛋白 Positive Control; Immunogen; SDS-PAGE; WB.
PAA788Hu01 细胞程序性死亡蛋白1配体1(PDL1)多克隆抗体 WB,ICC/IF
FAA788Hu01 抗细胞程序性死亡蛋白1配体1(PDL1)多克隆抗体 Flow cytometry.
FAA788Hu41 抗细胞程序性死亡蛋白1配体1(PDL1)多克隆抗体(藻红素标记) Flow cytometry.
FAA788Hu51 抗细胞程序性死亡蛋白1配体1(PDL1)多克隆抗体(别藻蓝蛋白标记) Flow cytometry.
FAA788Hu81 抗细胞程序性死亡蛋白1配体1(PDL1)多克隆抗体(异硫氰酸荧光素标记) Flow cytometry.
MAA788Hu28 细胞程序性死亡蛋白1配体1(PDL1)单克隆抗体 WB; IHC; ICC; IP.
MAA788Hu22 细胞程序性死亡蛋白1配体1(PDL1)单克隆抗体 WB; IHC; ICC; IP.
RAA788Hu22 细胞程序性死亡蛋白1配体1(PDL1)重组抗体 WB; IF; ICC; IHC; IP; FCM.
MAA788Hu21 细胞程序性死亡蛋白1配体1(PDL1)单克隆抗体 WB; IHC; ICC; IP.
MAA788Hu23 细胞程序性死亡蛋白1配体1(PDL1)单克隆抗体 WB; IHC; ICC; IP.
MAA788Hu24 细胞程序性死亡蛋白1配体1(PDL1)单克隆抗体 WB; IHC; ICC; IP.
MAA788Hu25 细胞程序性死亡蛋白1配体1(PDL1)单克隆抗体 WB; IHC; ICC; IP.
MAA788Hu27 细胞程序性死亡蛋白1配体1(PDL1)单克隆抗体 WB; IHC; ICC; IP.
MAA788Hu29 细胞程序性死亡蛋白1配体1(PDL1)单克隆抗体 WB; IHC; ICC; IP.
MAA788Hu26 细胞程序性死亡蛋白1配体1(PDL1)单克隆抗体 WB; IHC; ICC; IP.
RAA788Hu21 细胞程序性死亡蛋白1配体1(PDL1)重组抗体 WB; IF; ICC; IHC; IP; FCM.
LAA788Hu72 细胞程序性死亡蛋白1配体1(PDL1)单克隆抗体(生物素标记) WB; IHC; ICC.
FAA788Hu82 抗细胞程序性死亡蛋白1配体1(PDL1)单克隆抗体(异硫氰酸荧光素标记) Flow cytometry.
WEA788Hu 细胞程序性死亡蛋白1配体1(PDL1)检测试剂盒(酶联免疫吸附试验法,宽范围) Enzyme-linked immunosorbent assay for Antigen Detection.
SEA788Hu 细胞程序性死亡蛋白1配体1(PDL1)检测试剂盒(酶联免疫吸附试验法) Enzyme-linked immunosorbent assay for Antigen Detection.
SCA788Hu 细胞程序性死亡蛋白1配体1(PDL1)检测试剂盒(化学发光免疫分析法) Chemiluminescent immunoassay for Antigen Detection.
LMA788Hu 细胞程序性死亡蛋白1配体1(PDL1)等多因子检测试剂盒(流式荧光发光法) FLIA Kit for Antigen Detection.
PSA788Hu01 细胞程序性死亡蛋白1配体1(PDL1)抗体对 ELISA; CLIA; ELISPOT; Luminex; Immunochromatography and other Immunoassays.
KSA788Hu01 细胞程序性死亡蛋白1配体1(PDL1)检测试剂盒DIY材料(酶联免疫吸附试验法) Main materials for "Do It (ELISA Kit) Yourself".

参考文献

杂志 参考文献
Chinese Journal of Cancer Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications [NCBI: PMC3937742]
Leukemia.? High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. [Pubmed:24732592]
Diabetes?Metab Res Rev. PD‐L1 gene polymorphisms and low serum level of PD‐L1 protein are associated to type 1 diabetes in Chile [Pubmed:24816853]
Lancet Haematol Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study [PubMed: 26686046]
Eur J Cancer.  High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. [Pubmed:27039170]
Journal of Cancer Research and Clinical Oncology Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer [article:10.1007]
Journal of Hematology & Oncology PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma [pubmed:27737703]
Lung Cancer. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer. [pubmed:28212990]
Oncotarget Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predictssurvival in advanced biliary tract cancer patients treated with palliative chemotherapy. [pubmed:27780932]
Oncotarget High post-treatment serum levels of soluble programmed cell death ligand 1 predict earlyrelapse and poor prognosis in extranodal NK/T cell lymphoma patients. [pubmed:27105512]
Oncotarget.  Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma [pubmed:27566569]
Cancer Immunol Immunother. Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy. [pubmed:28349165]
Leukemia Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients [leu2016385a]
Medicine Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy. [pubmed:28207525]
Allergology International  Inverse correlation of soluble programmed cell death-1 ligand-1 (sPD-L1) with eosinophil count and clinical severity in allergic rhinitis patients [pubmed:27617656]
Medicine Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy [PMC5319514]
American Journal of Respiratory and Critical Care Medicine Soluble Programed Death Receptor 1 Ligand (sPD-L1) in Pleural Fluid of Patients with Malignant Pleural Mesothelioma (MPM) [Pdf:10.1164]
Clinical Lung Cancer Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non–Small-cell Lung Cancer [Pubmed:29859759]
Journal of Rheumatology Increased levels of soluble programmed death ligand 1 associate with malignancy in patients with dermatomyositis [Pubmed:29419471]
Translational Oncology High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma [Pubmed:29698935]
Immunology Letters Increased levels of soluble co-stimulatory molecule PD-L1 (B7-H1) in the plasma of viraemic HIV-1+ individuals [Pubmed: 30236481]
Journal of Cancer Research and Clinical Oncology Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma [Pubmed: 30267213]
Annals of Surgical Oncology Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between … [Pubmed: 30565045]
American Journal of Reproductive Immunology Identification of programmed cell death 1 and its ligand in the testicular tissue of mice [Pubmed: 30578744]
PLoS One Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated … [Pubmed: 30807610]
Endocrine Connections Elevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer [Pubmed: 31252406]
Scientific Reports Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer [Pubmed: 31366979]
Critical Reviews in Oncology / Hematology The Clinical Significance of Soluble PD-1 and PD-L1 in Lung Cancer [Pubmed: 31675543]
PLoS One Clinical implications of APOBEC3A and 3B expression in patients with breast cancer [Pubmed: 32176735]
Cancers Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study [Pubmed: 32085544]
Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma [Pubmed: 32054467]
LIVER INTERNATIONAL The prognostic role of soluble transforming growth factor‐β and its correlation with soluble programmed death‐ligand 1 in biliary tract cancer [Pubmed: 32780918]
CANCER IMMUNOLOGY IMMUNOTHERAPY Prognostic impacts of tumoral expression and serum levels of PD-L1 and CTLA-4 in colorectal cancer patients [Pubmed: 32577816]
Soluble PD-L1: a potential immune marker for HIV-1 infection and virological failure [Pubmed: 32443313]
Cancer Immunol Immunother The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte [33688997]
Acta Biochim Biophys Sin Prognostic prospect of soluble programmed cell death ligand-1 (sPD-L1) in cancer management [34180502]
EMBO J Microglial PD‐1 stimulation by astrocytic PD‐L1 suppresses neuroinflammation and Alzheimer's disease pathology [34825707]
Mol Pharm A Novel Small Cyclic Peptide-Based 68Ga-Radiotracer for Positron Emission Tomography Imaging of PD-L1 Expression in Tumors [34910492]
Mol Hum Reprod Macrophage Associated Immune Checkpoint CD47 Blocking Ameliorates Endometriosis [Pubmed:35404426]
Journal of Nanobiotechnology Microbial hydrogen “manufactory” for enhanced gas therapy and self-activated immunotherapy via reduced immune escape [Pubmed:35705974]
Medicina Assessment of the RANTES Level Correlation and Selected Inflammatory and Pro-Angiogenic Molecules Evaluation of Their Influence on CRC Clinical Features: A … [Pubmed:35208526]
留言咨询